Non-Aqueous Nitrazepam Oral Solution for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral pharmaceutical formulations of nitrazepam are chemically unstable, particularly susceptible to hydrolysis, oxidation, and require refrigeration, limiting their shelf life and increasing treatment costs.
Innovation Solution
A non-aqueous oral pharmaceutical solution comprising nitrazepam and a non-aqueous liquid carrier of medium-chain fatty acid triglycerides, which enhances physicochemical stability and prevents decomposition during extended storage at room temperature.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If nitrazepam is formulated as an oral suspension, then it becomes available in liquid form for administration, but it requires refrigeration which increases treatment costs and reduces availability
Solution Approach 1:
The patent changes the physical-chemical parameters of the formulation by using a non-aqueous liquid carrier (medium-chain triglycerides) instead of aqueous suspension. This parameter change eliminates the need for refrigeration while maintaining liquid form, resolving the contradiction between ease of administration and storage stability
Solution Approach 2:
The patent creates a composite formulation by dissolving nitrazepam in medium-chain triglycerides (such as caprylic triglyceride or capric triglyceride). This composite non-aqueous system provides both liquid form for easy administration and stability at room temperature, simultaneously addressing both requirements
2Reliability
If nitrazepam is stored at normal conditions (20 to 25°C), then treatment costs are reduced and availability increases, but the drug becomes unstable and degrades
Solution Approach 1:
The patent changes the formulation parameters to a non-aqueous system with medium-chain triglycerides, which fundamentally alters the stability profile of nitrazepam. This enables the drug to maintain stability at higher temperatures (20-25°C) without refrigeration, resolving the contradiction between stability and temperature requirement
3Ease of operation
If nitrazepam is formulated in water-based solution, then it is easier to administer, but it becomes susceptible to hydrolysis and oxidation reducing shelf life
Solution Approach 1:
The patent changes the fundamental parameter of the carrier medium from aqueous to non-aqueous (medium-chain triglycerides). This eliminates water-related degradation pathways (hydrolysis and oxidation) while maintaining liquid form for easy administration, resolving the contradiction between administration ease and chemical stability
Solution Approach 2:
The non-aqueous medium-chain triglyceride carrier creates an inert chemical environment that protects nitrazepam from water-mediated degradation reactions. This inert environment maintains chemical stability while preserving the liquid formulation benefits
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable nitrazepam formulation with improved resistance to hydrolysis and oxidation, maintaining efficacy over extended periods without refrigeration, thus reducing treatment costs and increasing availability.
Implementation Method 1
The oral pharmaceutical solution according to the invention exhibits excellent physicochemical stability. The present invention has the advantage that it provides a stable oral pharmaceutical solution of nitrazepam, by inhibiting hydrolysis and oxidation that typically occur after extended storage.
Implementation Method 2
The present invention has the advantage that it provides a stable oral pharmaceutical solution of nitrazepam, by inhibiting hydrolysis and oxidation that typically occur after extended storage.
Data Source
AI summary
An oral pharmaceutical solution comprising nitrazepam and a non-aqueous liquid carrier comprising one or more medium-chain fatty acid triglycerides.